Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients

This study has been completed.

Sponsor:

Collaborator:

University of Turin, Italy

Information provided by (Responsible Party):

Paolo Zola, Azienda Ospedaliera San Giovanni Battista

ClinicalTrials.gov Identifier:

NCT01523652

First received: July 5, 2011

Last updated: January 30, 2012

Last verified: January 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	November 2008
Estimated Primary Completion Date:	No date given

No publications provided by Azienda Ospedaliera San Giovanni Battista

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Surbone A, Fuso L, Passera R, Ferrero A, Marchese C, Martino C, Luchin A, Di Renzo MF, Zola P. Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. BMC Res Notes. 2012 Sep 23;5:517. doi: 10.1186/1756-0500-5-517.

To Top